Open AccessInhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders
Author(s) -
Daniel Aeberli,
Stefan Oertle,
Heribert Mauron,
Stephan Reichenbach,
Beat Jordi,
Peter M. Villiger
Publication year - 2002
Publication title -
schweizerische medizinische wochenschrift
Language(s) - English
Resource type - Journals
ISSN - 0036-7672
DOI - 10.4414/smw.2002.10031
Subject(s) - medicine , etanercept , infliximab , rheumatoid arthritis , macrophage activation syndrome , immunology , arthritis , tumor necrosis factor alpha , disease
To examine the potential of the two tumour necrosis factor (TNF) inhibitors infliximab and etanercept as remission-inducing agents in chronic therapy-resistant inflammatory disorders of immune or non-immune pathogenesis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom